Sweden's Elekta returns to annual profit
This article was originally published in Clinica
Executive Summary
Europe's market leader in radiation oncology and neurosurgery, Elekta, returned to profit as annual sales rose 26% to SKr2,160 million ($205 million). The company sustained an operating loss of SKr37 million and net loss of SKr77 million last year, but this year reported SKr92 million and SKr61 million profit respectively.